Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Total Current Liabilities: 2012-2024

Historic Total Current Liabilities for Ptc Therapeutics (PTCT) over the last 13 years, with Dec 2024 value amounting to $581.0 million.

  • Ptc Therapeutics' Total Current Liabilities rose 41.84% to $866.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $866.2 million, marking a year-over-year increase of 41.84%. This contributed to the annual value of $581.0 million for FY2024, which is 3.67% down from last year.
  • As of FY2024, Ptc Therapeutics' Total Current Liabilities stood at $581.0 million, which was down 3.67% from $603.1 million recorded in FY2023.
  • In the past 5 years, Ptc Therapeutics' Total Current Liabilities registered a high of $603.1 million during FY2023, and its lowest value of $277.3 million during FY2020.
  • Moreover, its 3-year median value for Total Current Liabilities was $581.0 million (2024), whereas its average is $530.1 million.
  • Per our database at Business Quant, Ptc Therapeutics' Total Current Liabilities spiked by 83.66% in 2021 and then declined by 20.24% in 2022.
  • Ptc Therapeutics' Total Current Liabilities (Yearly) stood at $277.3 million in 2020, then surged by 83.66% to $509.3 million in 2021, then decreased by 20.24% to $406.2 million in 2022, then spiked by 48.46% to $603.1 million in 2023, then fell by 3.67% to $581.0 million in 2024.